A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MOMA 313 (Primary) ; Olaparib
Indications Advanced breast cancer; Male breast cancer; Pancreatic cancer; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors MOMA Therapeutics

08 Jan 2025 According to a MOMA Therapeutics media release, initial readout of olaparib combination efficacy data is anticipated in mid-2026, with development of the proprietary combination with MOMA-989 to initiate in late 2026.
19 Aug 2024 According to a MOMA Therapeutics media release, company announced that the First patient dosed in its first-in-human study of MOMA-313.
19 Aug 2024 Status changed from not yet recruiting to recruiting acording to a MOMA Therapeutics Spinogenix media release..

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com